HDAC2 and colorectal carcinoma: HDACs, such as HDAC2, have been found to be overexpressed in CRC, correlating with poor prognosis, and HDAC inhibitors (HDACis), such as vorinostat and trichostatin A (TSA), have shown therapeutic potential in preclinical CRC models.180